Program for Global Public Health and the Common Good, Boston College, 140 Commonwealth Avenue / Higgins Hall, Suite 648, Chestnut Hill, MA, 02467, USA.
Global Observatory on Pollution and Health, Boston College, 140 Commonwealth Avenue / Higgins Hall, Suite 648, Chestnut Hill, MA, 02467, USA.
Environ Health. 2021 Apr 12;20(1):42. doi: 10.1186/s12940-021-00725-y.
Aspartame is one of the world's most widely used artificial sweeteners and is an ingredient in more than 5000 food products globally. A particularly important use is in low-calorie beverages consumed by children and pregnant women. The Ramazzini Institute (RI) reported in 2006 and 2007 that aspartame causes dose-related increases in malignant tumors in multiple organs in rats and mice. Increased cancer risk was seen even at low exposure levels approaching the Acceptable Daily Intake (ADI). Prenatal exposures caused increased malignancies in rodent offspring at lower doses than in adults. These findings generated intense controversy focused on the accuracy of RI's diagnoses of hematopoietic and lymphoid tissue tumors (HLTs). Critics made the claim that pulmonary lesions observed in aspartame-exposed animals were inflammatory lesions caused by Mycoplasma infection rather than malignant neoplasms.
To address this question, RI subjected all HLTs from aspartame-exposed animals to immunohistochemical analysis using a battery of markers and to morphological reassessment using the most recent Internationally Harmonized Nomenclature and Diagnostic (INHAND) criteria.
This immunohistochemical and morphological re-evaluation confirmed the original diagnoses of malignancy in 92.3% of cases. Six lesions originally diagnosed as lymphoma (8% of all HLTs) were reclassified: 3 to lymphoid hyperplasia, and 3 to chronic inflammation with fibrosis. There was no evidence of Mycoplasma infection.
These new findings confirm that aspartame is a chemical carcinogen in rodents. They confirm the very worrisome finding that prenatal exposure to aspartame increases cancer risk in rodent offspring. They validate the conclusions of the original RI studies. These findings are of great importance for public health. In light of them, we encourage all national and international public health agencies to urgently reexamine their assessments of aspartame's health risks - especially the risks of prenatal and early postnatal exposures. We call upon food agencies to reassess Acceptable Daily Intake (ADI) levels for aspartame. We note that an Advisory Group to the International Agency for Research on Cancer has recommended high-priority reevaluation of aspartame's carcinogenicity to humans.
阿斯巴甜是世界上使用最广泛的人工甜味剂之一,也是全球 5000 多种食品的成分。一个特别重要的用途是在儿童和孕妇饮用的低热量饮料中使用。拉马齐尼研究所(RI)在 2006 年和 2007 年报告称,阿斯巴甜会导致老鼠和老鼠的多个器官中的恶性肿瘤与剂量有关的增加。即使在接近可接受的每日摄入量(ADI)的低暴露水平下,也会看到癌症风险增加。在较低剂量下,产前暴露会导致啮齿动物后代的恶性肿瘤增加,而在成年人中则不会。这些发现引发了激烈的争议,焦点集中在 RI 对造血和淋巴组织肿瘤(HLT)的诊断准确性上。批评者声称,在暴露于阿斯巴甜的动物中观察到的肺部病变是由支原体感染引起的炎症性病变,而不是恶性肿瘤。
为了解决这个问题,RI 对所有暴露于阿斯巴甜的动物的 HLT 进行了免疫组织化学分析,使用了一系列标记物,并使用最新的国际协调命名和诊断(INHAND)标准进行了形态学重新评估。
这种免疫组织化学和形态学重新评估证实了 92.3%的病例的恶性肿瘤的原始诊断。最初诊断为淋巴瘤的 6 个病变(所有 HLT 的 8%)被重新分类:3 个为淋巴组织增生,3 个为纤维化的慢性炎症。没有支原体感染的证据。
这些新发现证实阿斯巴甜是啮齿动物的化学致癌物。它们证实了非常令人担忧的发现,即产前暴露于阿斯巴甜会增加啮齿动物后代的癌症风险。它们验证了原始 RI 研究的结论。这些发现对公共卫生具有重要意义。鉴于这些发现,我们鼓励所有国家和国际公共卫生机构紧急重新审查他们对阿斯巴甜健康风险的评估 - 特别是对产前和产后早期暴露的风险。我们呼吁食品机构重新评估阿斯巴甜的可接受日摄入量(ADI)水平。我们注意到,国际癌症研究机构的一个咨询小组建议优先重新评估阿斯巴甜对人类的致癌性。